Suppression of myoclonus in SCA2 by piracetam
Copyright policy )Suppression of myoclonus in SCA2 by piracetam
AbstractWe report on a 30‐year‐old patient with advanced cerebellar degeneration due to SCA2. He presented with severe myoclonus, which was resistant to conventional therapy and dramatically improved after administration of 12–18 gm/die piracetam. Piracetam may be considered in the treatment of refractory myoclonus in spinocerebellar degenerations. © 2005 Movement Disorder Society
Adult, Gait Ataxia, Male, Myoclonus, Adult, Ataxia; drug therapy/genetics, Dose-Response Relationship; Drug, Gait Ataxia; drug therapy/genetics, Humans, Infusions; Intravenous, Male, Myoclonus; drug therapy/genetics, Nerve Tissue Proteins; genetics, Neurologic Examination; drug effects, Piracetam; adverse effects/therapeutic use, Recurrence, Spinocerebellar Ataxias; drug therapy/genetics, Substance Withdrawal Syndrome; diagnosis, Treatment Outcome, Trinucleotide Repeats; genetics, Infusions, diagnosis, Nerve Tissue Proteins, Dose-Response Relationship, drug therapy/genetics, Trinucleotide Repeats, Recurrence, Humans, Spinocerebellar Ataxias, genetics, Infusions, Intravenous, Neurologic Examination, Dose-Response Relationship, Drug, Piracetam, Substance Withdrawal Syndrome, adverse effects/therapeutic use, Treatment Outcome, Ataxins, drug effects, Ataxia, Drug, Intravenous
Adult, Gait Ataxia, Male, Myoclonus, Adult, Ataxia; drug therapy/genetics, Dose-Response Relationship; Drug, Gait Ataxia; drug therapy/genetics, Humans, Infusions; Intravenous, Male, Myoclonus; drug therapy/genetics, Nerve Tissue Proteins; genetics, Neurologic Examination; drug effects, Piracetam; adverse effects/therapeutic use, Recurrence, Spinocerebellar Ataxias; drug therapy/genetics, Substance Withdrawal Syndrome; diagnosis, Treatment Outcome, Trinucleotide Repeats; genetics, Infusions, diagnosis, Nerve Tissue Proteins, Dose-Response Relationship, drug therapy/genetics, Trinucleotide Repeats, Recurrence, Humans, Spinocerebellar Ataxias, genetics, Infusions, Intravenous, Neurologic Examination, Dose-Response Relationship, Drug, Piracetam, Substance Withdrawal Syndrome, adverse effects/therapeutic use, Treatment Outcome, Ataxins, drug effects, Ataxia, Drug, Intravenous
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).12 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!